11:02:46 EST Tue 17 Nov 2026
Enter Symbol
or Name
USA
CA



Co-Diagnostics Receives Logix Smart® ZDC Test Order from Peru Distributor as Dengue Cases Rise and Exhibits at MEDICA 2026 in Düsseldorf

2026-11-17 09:00 ET - News Release

Co-Diagnostics Receives Logix Smart® ZDC Test Order from Peru Distributor as Dengue Cases Rise and Exhibits at MEDICA 2026 in Düsseldorf

PR Newswire

Company Also Ships Logix Smart ZDC Tests for Study in Bolivia

Co-Dx to Meet with International Customers and Distributors at World Trade Center Utah Booth

SALT LAKE CITY, Nov. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its distributor in Peru has placed a new order for its Logix Smart® ZDC (ZIKV-DENV-CHIKV) test as the country experiences a rise in dengue activity, and shipped Logix Smart® ZDC tests purchased by a European organization for use in a study in Bolivia. The Company is also exhibiting at MEDICA 2026, taking place November 16-19 in Düsseldorf, Germany.

In Peru, the Company's distributor recently placed a new order for the Logix Smart ZDC test as the country experiences a rise in dengue activity. According to the Pan American Health Organization (PAHO), Peru has reported 83,430 dengue cases in 2026 through epidemiological week 42, and cases reported that week were up 51% compared with the average of the previous four weeks.

In Bolivia, the tests were purchased by a European organization for a study in collaboration with a prominent laboratory in Bolivia. Co-Dx also continues to supply real-time PCR instruments to its distributor in Bolivia, with approximately 17 units shipped since the beginning of 2025.

The Logix Smart ZDC test is a real-time RT-PCR test that uses the Company's patented Co-Primers® technology to detect and differentiate between Zika, dengue and chikungunya viruses, which are spread by mosquitoes and often present with similar symptoms. The test has been CE-IVD marked since 2019 and is available for sale in the European Union and other markets that accept CE-IVD marking. It is not available for sale in the United States.

"New orders for our Logix Smart ZDC test in South America reflect the need for a multiplex CE-IVD marked assay that detects and differentiates Zika, dengue and chikungunya," said Dwight Egan, Chief Executive Officer of Co-Diagnostics. "These orders put our technology to work in regions where these mosquito-borne diseases are a public health concern. MEDICA gives our team direct access to the customers and distributors who drive our international business, and we are in Düsseldorf this week to build those relationships."

Co-Dx is exhibiting at MEDICA 2026 as part of the World Trade Center Utah booth at Stand 16E24-1 in Hall 16. MEDICA is one of the world's largest trade fairs for medical technology and healthcare, drawing international exhibitors across diagnostics, laboratory equipment and health IT. Co-Dx has exhibited at MEDICA several times, and the event is a key meeting point with customers and distributors from South Asia and the Middle East, two of the Company's main target markets.

"Success in global business comes to those who show up," said World Trade Center Utah," said Jonathan Freedman, President and CEO of World Trade Center Utah. "International trade shows like MEDICA put companies face-to-face with the customers, distributors and partners who can drive their next stage of growth. At World Trade Center Utah, we help businesses like Co-Diagnostics make those connections and turn global opportunities into business results. We're excited to see what comes from their participation at MEDICA and the relationships they build along the way."

Co-Dx is also hosting two webinars today: one for potential customers of its Vector Smart™ mosquito surveillance solutions, and one through CoSara Diagnostics, the Company's joint venture in India, on HPV and cervical cancer screening in recognition of World Cervical Cancer Elimination Day. For more information about either webinar, please contact info@co-dx.com.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, the Company's participation in MEDICA 2026 and its ability to engage customers and distributors in its target markets; the use of the Logix Smart ZDC test in a study in Bolivia; the Company's ability to generate additional orders for the Logix Smart ZDC test and its other products in South America and other markets; the Company's continued supply of real-time PCR instruments to its distributor in Bolivia; the Company's ability to support laboratories in regions where Zika, dengue and chikungunya are a public health concern; and the Company's planned webinars. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks that market demand or public health conditions may change; risks that epidemiological data referenced in this press release are preliminary and subject to revision; risks that participation in trade fairs or webinars may not result in new customers, distribution relationships or sales; risks that orders from distributors or other purchasers may not recur or may be reduced; risks that the study in Bolivia may not be completed as planned or may not lead to additional orders; risks that distribution partners may not successfully market, promote, or sell the Company's or its joint venture's products; risks associated with international operations, including changing regulatory requirements, economic conditions, reimbursement environments, import/export restrictions, and foreign currency fluctuations; risks related to maintaining CE-IVD marking and other regulatory authorizations for the Company's products, including under evolving European regulatory requirements; risks related to the performance, reliability, and market acceptance of the Logix Smart and Vector Smart product lines and other Co-Dx technologies; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-receives-logix-smart-zdc-test-order-from-peru-distributor-as-dengue-cases-rise-and-exhibits-at-medica-2026-in-dusseldorf-302942000.html

SOURCE Co-Diagnostics

Contact:

Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications, +1 212.896.1254, CODX@KCSA.com; Media Contact: Jennifer Webb, ColtrinMethod PR, jcoltrin@coltrinmethodpr.com

© 2026 Canjex Publishing Ltd. All rights reserved.